Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug 27;14(1):149.
doi: 10.1038/s41408-024-01129-0.

Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel

Rahul Banerjee  1   2 , Yelak Biru  3 , Craig E Cole  4 , Beth Faiman  5 , Shonali Midha  6 , Sikander Ailawadhi  7
Affiliations
Review

Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel

Rahul Banerjee et al. Blood Cancer J. .

Abstract

Many studies have documented racial, socioeconomic, geographic, and other disparities for United States (US) patients with multiple myeloma pertaining to diagnosis and frontline management. In contrast, very little is known about disparities in the management of relapsed/refractory multiple myeloma (RRMM) despite a plethora of novel treatment options. In this review, we discuss the manifestations of disparities in RRMM and strategies to mitigate their impact. Immunomodulatory drugs can create disparities on many axes, for example inappropriately low dosing due to Duffy-null status as well as time toxicity and financial toxicity from logistical hurdles for socioeconomically vulnerable patients. Access to myeloma expertise at high-volume centers is a critical consideration given the disconnect between how drugs like carfilzomib and dexamethasone are prescribed in trials versus optimized in real-world practice to lower toxicities. Disparities in chimeric antigen receptor T-cell therapy and bispecific antibody therapy span across racial, ethnic, and socioeconomic lines in large part due to their limited availability outside of high-volume centers. Another insidious source of disparities is supportive care in RRMM, ranging from inadequate pain control in Black patients to limited primary care provider access in rural settings. We discuss the rationales and evidence base for several solutions aimed at mitigating these disparities: for example, (1) bidirectional co-management with community-based oncologists, (2) screening for risk factors based on social determinants of health, (3) strategies to build patient trust with regard to clinical trials, and (4) longitudinal access to a primary care provider. As the treatment landscape for RRMM continues to expand, these types of efforts by the field will help ensure that this landscape is equally accessible and traversable for all US patients.

PubMed Disclaimer

Conflict of interest statement

RB reports consulting: Adaptive Biotech, BMS, Caribou Biosciences, Genentech, GSK, Janssen, Karyopharm, Legend Biotech, Pfizer, Sanofi, SparkCures; research: Abbvie, BMS, Janssen, Novartis, Pack Health, Prothena, Sanofi. CEC reports consulting: AbbVie, Binding Site, Genentech, GSK, Janssen, Pfizer: research, GSK. BF reports consulting: BMS, GSK, Janssen, Karyopharm, Sanofi. SM reports consulting: Pfizer, stock ownership: AbbVie. SA reports consulting: BeiGene, BMS, Cellectar, GSK, Janssen, Pfizer, Regeneron, Sanofi, Takeda; research: AbbVie, Amgen, Ascentage, BMS, Cellectar, GSK, Janssen, Pharmacyclics, Sanofi. The remaining authors have no disclosures.

Figures

Fig. 1
Fig. 1. Representative disparities in relapsed/refractory multiple myeloma.
ASCT autologous stem cell transplantation, CAR-T chimeric antigen receptor T-cell therapy, MM multiple myeloma, PCP primary care provider.
See this image and copyright information in PMC

References

    1. Bhutani M, Blue BJ, Cole C, Badros AZ, Usmani SZ, Nooka AK, et al. Addressing the disparities: the approach to the African American patient with multiple myeloma. Blood Cancer J. 2023;13:189 10.1038/s41408-023-00961-0. 10.1038/s41408-023-00961-0 - DOI - PMC - PubMed
    1. Mikhael J, Bhutani M, Cole CE. Multiple Myeloma for the Primary Care Provider: A Practical Review to Promote Earlier Diagnosis Among Diverse Populations. Am J Med. 2023;136:33–41. 10.1016/j.amjmed.2022.08.030. 10.1016/j.amjmed.2022.08.030 - DOI - PubMed
    1. Cerchione C, Grant SJ, Ailawadhi S Partnering with all patients: ensuring shared decision making and evidence-based management for underrepresented groups with multiple myeloma. Am Soc Clin Oncol Educ Book. 2023;43. 10.1200/EDBK_390202. - PMC - PubMed
    1. Hartley-Brown M, Cole CE, Price P, Andreini M, Mulligan G, Young AQ, et al. Creating Equitable and Inclusive Clinical Trials for Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2024;24:32–39. 10.1016/j.clml.2023.09.004. 10.1016/j.clml.2023.09.004 - DOI - PubMed
    1. Blue B, Pierre A, Mikhael J. Culturally Responsive Care Delivery in Oncology: The Example of Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2023;23:651–9. 10.1016/j.clml.2023.05.005. 10.1016/j.clml.2023.05.005 - DOI - PubMed